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NADPH oxidases constitute a major source of superoxide anion (·O2 −) in hypertension. Several studies suggest an important role
of NADPH oxidases in diﬀerent eﬀects mediated by TGF-β1. In this study we show that chronic administration of P144, a peptide
synthesized from type III TGF-β1 receptor, significantly reduced the cardiac NADPH oxidase expression and activity as well as
in the nitrotyrosine levels observed in control spontaneously hypertensive rats (V-SHR) to levels similar to control normotensive
Wistar Kyoto rats. In addition, P144 was also able to reduce the significant increases in the expression of collagen type I protein and
mRNA observed in hearts from V-SHR. In addition, positive correlations between collagen expression, NADPH oxidase activity,
and nitrotyrosine levels were found in all animals. Finally, TGF-β 1-stimulated Rat-2 exhibited significant increases in NADPH
oxidase activity that was inhibited in the presence of P144. It could be concluded that the blockade of TGF-β 1 with P144 inhibited
cardiac NADPH oxidase in SHR, thus adding new data to elucidate the involvement of this enzyme in the profibrotic actions of
TGF-β 1.
1. Introduction
Hypertension is associated with multiple functional and
structural cardiovascular alterations [1, 2]. Among oth-
ers, these alterations are characterized by the progressive
accumulation of fibrillar collagen, namely, collagen type I,
in the myocardium of animals and humans with arterial
hypertension and left ventricular hypertrophy [3]. Although
the exact mechanism by which physiological collagen turns
into pathological fibrotic tissue is still unknown, there are
many studies that suggest an important role of the local
production of the transforming growth factor β 1 (TGF-β 1)
[4]. TGF-β 1 acts as a key fibrogenic cytokine in many tissues
by enhancing extracellular matrix synthesis [5].
Currently, in vitro studies have described that the acti-
vation of the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase system has a role in TGF-β 1-induced
eﬀects [6–9]. Moreover, the association of the NADPH oxi-
dase with TGF-β 1-induced fibrosis has been also observed in
several experimental models [10–13]. The NADPH oxidase
has been shown as a major source of superoxide anion
(·O2−) [14]. It consists of a membrane bound cytochrome
formed by a small subunit (p22phox) and a big (NOX1-5,
Duox1-2) subunit, and in some cases, cytoplasmic subunits
that upon phosphorylation bind to the cytochrome [15].
In the heart of rats, Nox2 and Nox4 NADPH isoforms are
expressed. There is evidence that the Nox2-dependent form
of the enzyme is inducible and generates ·O2−, especially by
humoral activation [15, 16]. The Nox4-dependent enzyme
seems to be constitutively active and may directly generate
hydrogen peroxide (H2O2) [17, 18].
It has been described that the synthetic peptide P144,
encompassing amino acids 730–743 from the human
membrane-proximal ligand-binding domain of TGF-β 1
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type III receptor, also called betaglycan, acts as a competitor
of TGF-β 1 type III receptor, sequestering TGF-β 1. P144
is able to inhibit fibrosis in a rat model of hepatic failure
as well as in a murine model of sclerodermia [19, 20].
Furthermore, our group has recently demonstrated that P144
prevents myocardial fibrosis and collagen type I synthesis in
experimental hypertension [21].
The possible interrelationship between TGF-β 1 and the
NADPH oxidase in cardiac damage has not yet been studied
in an experimental model of hypertension. Given that TGF-
β 1 is a major contributor to the development of structural
alterations in target organs of hypertension [22], we inves-
tigated whether the chronic treatment with P144 inhibits
cardiac NADPH oxidase and whether this eﬀect is associated
with the cardiac antifibrotic properties of the peptide.
2. Material andMethods
2.1. Animals. The study was in agreement with the Guide
for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication no.
85–23, revised 1996) [23], and was approved by the Ethical
Committee for Animal Experimentation of the University of
Navarra (090/05; 100/07). Rats were provided by Harlan UK
Limited (Bicester, UK). Ten-week-old maleWistar-kyoto rats
(WKY) (n = 10, V-WKY) and 10-week-old male sponta-
neously hypertensive rats (SHR) (n = 10, V-SHR) received
vehicle (saline solution) intraperitoneally for 12 weeks, and
then were sacrificed at the age of 22 weeks. In addition, 10-
week-old WKY (n = 10, P144-WKY) and 10-week-old SHR
(n = 10, P144-SHR) were treated with intraperitoneal P144
for 12 weeks and then sacrificed. The peptide was dissolved
in saline solution, and the concentration was adjusted for
the body weight to obtain an average daily dose of 1mg/kg
body weight/day. This dose was selected because it had
been demonstrated previously in rodents that P144 exhibits
hepatic and cutaneous antifibrotic activity at doses above
0.5mg/kg body weight/day [15, 16]. All rats were housed in
individual cages with free access to standard rat chow and tap
water in a quiet room with constant temperature (20–22◦C)
and humidity (50–60%). Before they were sacrificed by
decapitation, the rats were weighed and anaesthetized with
Ketamine 75mg/kg (Imalgene 1000, Merial) and Xylazine
5mg/kg (Rompun, Bayer).
2.2. Measurement of Blood Pressure. Systolic blood pressure
(SBP) and diastolic blood pressure (DBP) were measured
in all rats every 2 weeks by the standard tail-cuﬀ method
using an LE5007 Pressure Computer (Letica Scientific Instru-
ments).
2.3. Preparation of Tissue Samples. After sacrifice, hearts were
carefully excised and frozen at −80◦C for mRNA, enzymatic
activity, and protein analysis.
For NADPH oxidase activity and Western blot studies,
hearts were homogenated on ice in phosphate buﬀer saline
(50mM K2HPO4, 50mM KH2PO4, 0.001mM EDTA, and
proteases inhibitor pH = 7) with a glass/glass motor-
driven tissue homogenizer for 2 minutes. The homogenate
was centrifuged at 2000 g for 10 minutes. The pellet was
discarded, and the supernatant was stored at −80◦C. Protein
concentration was determined by the Lowry methodology.
2.4. NADPH Oxidase Activity. Chemiluminescence assays
with 10 μmol/L lucigenin and 200 μmol/L NADPH were
used to measure ·O2− production in 200 μg of tissue
homogenate. Luminescence was recorded during 10 minutes
in a tube luminometer (Berthold Detection System, Sirius).
A buﬀer blank was subtracted from each reading, and the
value of the area under the curve was used to quantify
chemiluminescence. Data are expressed as relative light units
(RLUs) produced per second per mg of protein.
2.5. Western Blot. To analyze the nitrotyrosine (NT) levels
and the expression of collagen type I and Nox4 and
Nox2 NADPH oxidase isoforms, proteins were separated
by electrophoresis. Membranes were incubated with specific
antibodies against Nox4 and Nox2 isoforms (Santa Cruz
Biotechnology, INC Santa Cruz), NT (Upstate Biotechnol-
ogy, Millipore), and collagen type I (Biogenesis) overnight
at 4◦C at a dilution of 1 : 1000. The membranes were incu-
bated with appropiated peroxidase-conjugated secondary
antibodies (GE Healthcare) for 1 hour at room temperature
(1 : 25000 anti-rabbit for Nox4, 1 : 10000 anti-mouse for
Nox2, 1 : 10000 anti-mouse for collagen type I, and 1 : 20000
anti-mouse for NT). Protein expression was visualized with
the ECL-Advanced chemiluminescence system (Amersham
Biosciences). Bands were analyzed using the Chemidoc
Detection System and the Quantity One software (Bio-Rad)
obtaining densitometric arbitrary units (AU). The blots were
reprobed with a monoclonal α-tubulin antibody (Santa Cruz
Biotechnology, INC Santa Cruz) as a control for loading.
Data are expressed as the relative expression to α-tubulin.
2.6. Real-Time RT-PCR. The messenger RNA (mRNA) was
isolated from total RNA with the Oligotex mRNA KIT
(Quiagen). A real-time PCR reaction was performed using
TaqMan Gene Expression probes: Nox4 (Rn 00585380),
Nox2 (Rn 00576710), p22phox (Rn 00577357), p47phox
(Rn 00586945), TGF-β 1 (Rn 00572010), fibronectin (Rn
00569575), type I collagen (Rn01463848), biglycan (Rn
01529736), connective tissue growth factor (CTGF, Rn
00573960), lysyl oxidase (LOX, Rn 01491829), and 18S
ribosomal RNA(Hs 03003631). Data were normalized to 18S
ribosomal RNA expression. Relative expression of mRNA
was determined by the 2−ΔΔCT method [24].
2.7. Cell Cultures and In Vitro Experiments. The Rat-2 fibrob-
last cell line was purchased from American Type Culture
Collection and maintained in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal bovine
serum (FBS, Invitrogen), Penicilin-Streptomicin solution
(Invitrogen), and Fungizone (Invitrogen). Rat-2 cells were
seeded at a density of 5.25 × 105 cells in T-25 tissue
culture flasks (Nunc) and allowed to adhere overnight. Cells
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were then incubated in reduced-serum medium (1% FBS)
for 24 h prior to TGF-β 1 stimulation. Four conditions
were used: (i) cells incubated in reduced serum media, (ii)
cells incubated in reduced serum media containing TGF-
β 1 (10 ng/mL), (iii) cells incubated in reduced serum
media containing P144 (200 μg/mL), and (iv) cells incubated
in reduced serum media containing TGF-β 1 (10 ng/mL)
and P144 (200 μg/mL), for 24 h prior to harvesting. After
treatment, cells were trypsinized and pelleted. The cell pellets
were washed in phosphate-buﬀered solution (Invitrogen)
and centrifuged at 1100 g for 5min at 4◦C and then used for
protein extraction.
NADPH oxidase activity was performed as above. In this
case, ·O2− production was measured on 10 μg of cell protein.
2.8. Statistical Analysis. Results are given as mean ± SEM.
To analyze the diﬀerences among the four groups, a one-
way ANOVA followed by a Scheﬀe’s test was performed once
normality had been proven (Shapiro-Wilks test); otherwise,
a nonparametric test (Kruskall-Wallis) followed by a Mann-
Whitney U-test (adjusting the alpha-level by Bonferroni
inequality) was used. Bivariate associations were performed
by Pearson’s correlation test. The statistical analysis was
carried out using the computer program SPSS for Windows
version 15.0.
3. Results
3.1. Eﬀects of P144 on Blood Pressure. Values of SBP and
DBP were elevated in V-SHR (SBP: 246.7± 3.6mmHg; DBP:
208.6 ± 5.9mmHg) at the age of 22 weeks compared with
V-WKY (SBP: 175.0 ± 3.5mmHg; DBP: 128.7 ± 7.1mmHg;
P < 0.01). Interestingly, at the age of 22 weeks, blood pressure
values were lower (P < 0.01) in P144-SHR (SBP: 215.6
± 5.9mmHg; DBP: 191.9 ± 4.5mmHg) than in V-SHR,
although they were still higher (P < 0.01) than in V-WKY.
No significant diﬀerences were observed between P144-WKY
(SBP: 160.8 ± 5.2mmHg; DBP: 126.9 ± 4.3mmHg) and V-
WKY.
3.2. Eﬀects of P144 on Cardiac NADPH Oxidase. Cardiac
NADPH oxidase activity was higher (P < 0.05) in V-SHR
than in V-WKY (Figure 1). The administration of P144
reduced (P < 0.05) NADPH oxidase activity in P144-SHR to
the V-WKY levels. No diﬀerences were found between P144-
WKY and V-WKY (Figure 1). Accordingly, cardiac mRNA
and protein levels of Nox2 (Figure 2) were higher (P <
0.05) in V-SHR than in V-WKY. Compared with V-SHR, the
administration of P144 reduced mRNA and protein levels of
Nox2 (Figure 2) in P144-SHR (P < 0.01) to levels similar
to V-WKY. Other NADPH oxidase subunits associated with
Nox2 NADPH oxidase isoform were also evaluated at mRNA
level. Cardiac abundance of p22phox and p47phox was
higher (P < 0.01) in V-SHR (2.26 ± 0.15 AU and 2.23 ±
0.21 AU, respectively) than in V-WKY (1.00 ± 0.09 AU for
p22phox and 1.00 ± 0.08 AU for p47phox). In the same line
as the NADPH oxidase activity results, the administration of
P144 reduced (P < 0.01) the mRNA expression of p22phox
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Figure 1: Eﬀect of P144 on cardiac NADPH oxidase activity. Car-
diac NADPH oxidase-dependent ·O2− production was determined
by chemiluminescence in the presence of NADPH 200 μmol/L,
and it is expressed as relative light units per second (RLU/s).
Histogram represents mean ± SEM (n = 10). V-WKY means
vehicle-treated normotensive rat; P144-WKY, P144-treated WKY
rat; V-SHR, vehicle-treated spontaneously hypertensive rat, P144-
SHR, P144-treated SHR. ∗P < 0.05 versus the other groups.
and p47phox on P144-SHR group (1.47± 0.1 AU and 0.99±
0.23 AU, respectively) to levels similar to V-WKY.
Interestingly, cardiac mRNA and protein levels of Nox4
NADPH oxidase isoform (Figure 3) were higher (P <
0.05) in V-SHR than in V-WKY. Compared with V-SHR,
the administration of P144 reduced expression of Nox4
(Figure 3) in P144-SHR (P < 0.01) to levels similar to V-
WKY.
3.3. Eﬀects of P144 on Cardiac Levels of Nitrotyrosine. Since
nitrosylation of proteins is considered a consequence of
oxidative stress, the levels of nitrotyrosilated proteins were
quantified by Western blot. Following the same pattern
that the NADPH oxidase activity determined in heart
homogenates, the NT levels were higher (P < 0.05) in the
V-SHR group than in V-WKY (Figure 4(a)). Similarly, the
administration of P144 reduced (P < 0.05) the levels of
NT expression in P144-SHR. The levels of nitrotyrosilated
proteins were similar between V-WKY and P144-SHR.
A direct correlation was found between the cardiac
NADPH oxidase activity and NT levels in all the rats (r =
0.407, P < 0.01), suggesting that the NADPH oxidase
overactivity may play an important role in the development
of cardiac oxidative stress in this model of hypertension
(Figure 4(b)).
3.4. Eﬀects of P144 on Cardiac Collagen Metabolism. Cardiac
collagen type I protein expression and mRNA levels were
higher (P < 0.05) in V-SHR than in V-WKY (Figure 5).
The administration of P144 reduced cardiac collagen type I
protein expression in P144-SHR. No diﬀerences were found
between P144-WKY and V-WKY (Figure 5).
The mRNA expression of TGF-β 1, CTGF, fibronectin,
biglycan and LOX was higher (P < 0.01) in V-SHR than in
V-WKY. The chronic administration of P144 resulted in a
decreased expression (P < 0.05) of the mRNA levels of these
molecules (Figure 6).
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Figure 2: Eﬀect of P144 on cardiac Nox2 subunit expression. (a) mRNA levels of Nox2 expressed as a ratio of gene to 18S values from rat
heart. (b) Expression of the Nox2 protein levels relative to α-tubulin in the rat heart. Representative western blot of the four groups of rats
are shown at the upper part. Histograms represent mean ± SEM (n = 10). V-WKY means vehicle-treated normotensive rat; P144-WKY,
P144-treated WKY rat; V-SHR, vehicle-treated spontaneously hypertensive rat; P144-SHR, P144-treated SHR. ∗P < 0.05 versus the other
groups.
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Figure 3: Eﬀect of P144 on cardiac Nox4 subunit expression. (a) mRNA levels of Nox4 expressed as a ratio of gene to 18S values from
rat heart. (b) Expression of Nox4 protein levels relative to α-tubulin in the rat heart. Representative western blot of the four groups of rats
is shown at the upper part. Histograms represent mean ± SEM (n = 10). V-WKY means vehicle-treated normotensive rat; P144-WKY,
P144-treated WKY rat; V-SHR, vehicle-treated spontaneously hypertensive rat; P144-SHR, P144-treated SHR. ∗∗P < 0.01 versus the other
groups.
Moreover, combining data from all groups, direct posi-
tive correlations were found between collagen type I protein
expression and parameters assessing oxidative stress, that is,
NT levels (r = 0.384, P < 0.01) and NADPH oxidase activity
(r = 0.372, P < 0.05).
3.5. In Vitro Findings. In vitro studies showed that TGF-β
1 stimulated (P < 0.05) the NADPH oxidase activity in
Rat-2 fibroblasts (Figure 7). Interestingly, P144 completely
prevented the TGF-β1-induced NADPH oxidase activity
(Figure 7).
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Figure 4: Eﬀect of P144 on cardiac levels of nitrotyrosine (NT). (a) Levels of NT relative to α-tubulin in the rat heart. Representative western
blot of the four groups of rats are shown at the upper part. Histogram represents mean ± SEM (n = 10). (b) Positive correlation of cardiac
NADPH oxidase activity and levels of NT in all the rats (r = 0.407; P = 0.001; y = 0.0004x + 0.3797). RLU/s means relative light units
per second. V-WKY means vehicle-treated normotensive rat; P144-WKY, P144-treated WKY rat; V-SHR, vehicle-treated spontaneously
hypertensive rat; P144-SHR, P144-treated SHR. ∗P < 0.05 versus the other groups.
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Figure 5: Eﬀect of P144 on cardiac collagen type I expression. (a) mRNA levels of collagen type I expressed as a ratio of gene to 18S values
from rat heart. (b) Expression of the collagen type I protein relative to α-tubulin in the rat heart. Representative western blot of the four
groups of rats are shown at the upper part. Histograms represent mean ± SEM (n = 10). V-WKY means vehicle-treated normotensive rat;
P144-WKY, P144-treated WKY rat; V-SHR, vehicle-treated spontaneously hypertensive rat; P144-SHR, P144-treated SHR. ∗P < 0.05 and
∗P < 0.05 versus the other groups.
4. Discussion
The main findings of this study are as follows: (i) the chronic
administration of P144 inhibits NADPH oxidase activity and
expression, as well as NT-assessed oxidative stress in the heart
of SHR; (ii) the chronic administration of P144 prevents the
excessive expression of cardiac collagen type I and molecules
related to collagen synthesis in the same rats; (iii) P144 is
able to block the TGF-β 1-induced NADPH oxidase activity
in cultured rat fibroblasts. Collectively, these findings suggest
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Figure 6: Cardiac mRNA levels of genes assessing collagen
metabolism. Cardiac mRNA expression of TGF-β 1, connective
tissue growth factor (CTGF), fibronectin, biglycan, and lysyl oxidase
(LOX) as a ratio of gene to 18S values. Histogram represents mean
± SEM (n = 10). V-WKY means vehicle-treated normotensive
rat; P144-WKY, P144-treated WKY rat; V-SHR, vehicle-treated
spontaneously hypertensive rat; P144-SHR, P144-treated SHR.
∗P < 0.05 and ∗∗P < 0.01 versus V-WKY; †P < 0.05 and ††P < 0.01
versus V-SHR.
that interference with the TGF-β 1-NADPH oxidase axis by
P144 may contribute to the cardiac antifibrotic action of this
peptide.
Accumulating evidence indicates that NADPH oxidase
activity is increased in several animal models of heart disease
[25, 26]. In our study, increased NADPH oxidase activity
in V-SHR associated with upregulated Nox2 and associated
subunits, namely, p22phox and p47phox. In addition, the
elevation of cardiac NT levels in untreated V-SHR was
associated with a parallel increase in NADPH oxidase
activity, indicating an increase in oxidative stress in the
heart of V-SHR, presumably by NADPH oxidase activation.
Interestingly, an increased expression of Nox4 isoform was
also observed in the heart of V-SHR. Given that it has been
demonstrated that Nox4 NADPH oxidase isoform generates
mainly H2O2 [17], we can speculate that increased cardiac
NADPH oxidase activity on V-SHR was due to upregulation
of Nox2 isoform and its cytosolic components.
The TGF-β 1 type III receptor or betaglycan is the most
abundant TGF-β 1 binding protein at the cell surface [27].
Betaglycan potentiates TGF-β 1 binding to the signaling type
I and type II receptors and, therefore, may be involved in
ligand presentation [28]. Most of the research to prevent
fibrosis in hypertensive heart disease has been focused on
the eﬀectiveness of drugs interfering with the angiotensin
II-aldosterone-TGF-β 1 axis [29, 30]. In this context, our
group has developed a synthetic peptide from the sequence
of the extracellular region of human betaglycan, the P144,
which was predicted as a potential binder to TGF-β 1 by
a computer program [31]. We have recently demonstrated
that P144 prevents myocardial fibrosis and collagen type I
synthesis in SHR [21].
Diverse experimental approaches have suggested a key
role of TGF-β 1 in the activation of the NADPH oxidase. A
study in apolipoprotein E-deficient mice demonstrated that
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Figure 7: Eﬀect of P144 on TGF-β-1-induced NADPH oxidase
activity in Rat-2 fibroblasts. Cells were incubated with 10 ng/mL
TGF-β 1 (TGF-β 1), 200 μg/mL P144 (P144), and TGF-β 1 and P144
(TGF-β 1+P144). Data are expressed as fold increase versus control
cells incubated in the absence of TGF-β 1 and P144 (Control).
Histogram represents mean ± SEM (n = 10). ∗P < 0.05 versus the
other groups.
elevated systemic TGF-β 1 levels cause vascular alterations
through the NADPH oxidase activation [32]. In addition,
the treatment with benidipine of Dahl salt-sensitive rats
with heart failure prevented the cardiac dysfunction and
remodeling, which was associated with the suppression of
TGF-β 1 and inhibited the expression of NADPH oxidase
subunits [33]. In rat ventricular myocytes, the oxidative
stress caused by the NADPH oxidase system mediated the
cardiomyocyte contractile dysfunction caused by TGF-β 1
[34]. In agreement with these studies, we have observed
that the treatment with P144 prevented the NADPH oxidase
overactivity observed in SHR. In addition, our data showed
that the reduction of NADPH oxidase activity by chronic
treatment with P144 was associated with a significant
reduction of the NADPH oxidase subunit abundance and
diminished NT levels in the heart of P144-SHR. Thus,
P144 treatment appears to limit oxidative stress by lowering
NADPH oxidase abundance in the SHR heart to the levels
of the control strain. Studies in adult rat cardiac fibroblasts
have shown that NADPH oxidase inhibition blocked the
angiotensin II-stimulated collagen production [4]. Finally,
the generation of reactive oxygen species in response to Rac
has been demonstrated in Rat-2 fibroblasts [35]. Findings
from the current study expanded these data by showing that
P144 inhibits the ability of TGF-β 1 to stimulate NADPH
oxidase activity in the same cell line of rat fibroblasts.
Several studies have shown that a reduction in NADPH
oxidase activation was associated with reversed cardiac
damage in several experimental models [33, 36, 37]. In fact,
Wu et al. demonstrated that the antioxidant properties of
acetylsalicylic acid were closely associated with its protective
eﬀect against angiotensin II-induced cardiac hypertrophy
[26]. In addition, the combination of pioglitazone and
candesartan exerted beneficial eﬀects on cardiac fibrosis by
attenuating the NADPH oxidase activity [37]. The results of
the current study allow us to suggest that the antifibrotic
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actions of P144 in experimental hypertension may be asso-
ciated with its ability to block the TGF-β-1-induced NADPH
oxidase activation. Nevertheless, further experiments should
be performed to better address this possibility.
Some limitations of the current study must be recog-
nized. First, the dose of 1mg/kg body weight/day was selected
to study the eﬀects of P144 on NADPH oxidase-mediated
TGF-β 1 eﬀects. It was previously demonstrated that P144
exhibits hepatic and cutaneous antifibrotic activity at doses
above 0.5mg/kg body weight per day in rodents [19]. In fact,
other groups of SHR and WKY rats were previously treated
with P144 at the dose of 0.5mg/kg body weight per day,
and no antifibrotic eﬀect at cardiac level was observed (data
not shown). Second, although we did not determine H2O2
production, it has been proposed that levels of Nox4 protein
expression may be representative of Nox4-dependent H2O2
production. Finally, to better understand the link between
NADPH oxidase and collagen production, further data from
in vitro studies would be necessary.
In conclusion, the present results support that P144,
a peptide synthesized from type III TGF-β 1 receptor,
prevented NADPH oxidase-dependent oxidative stress and
fibrosis in hearts of SHR. Thus, P144 may be interesting as
a therapeutic agent for the protection of the heart against
oxidative stress and fibrosis in hypertension. Further studies
should be performed to better address this possibility.
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